KRTL HOLDING GROUP INC Stock Price, News & Analysis

KRTL (OTC: KRTL) announced that majority-owned KRTL Biotech is highlighting an expanded portfolio of anti-infective and antibiotic products developed with SIGMA Corp to support access to essential medicines in underserved and emerging markets.

Key facts: KRTL Biotech is 51% owned, products are manufactured at SIGMA’s GMP-certified Cochabamba facility, the global anti-infectives market is cited as >$150 billion annually, and the company is evaluating regulatory pathways including ANDA and international approvals for exports.

KRTL Biotech (OTC: KRTL) has announced its flagship hydration product ELIXIR as a major success in the Bolivian market. The GMP-compliant hydration beverage is currently available in over 7,000 retail locations throughout Bolivia, offering a scientifically formulated blend of electrolytes including glucose, sodium, potassium, calcium, magnesium, and citric acid.

ELIXIR comes in multiple flavors and formats, from sachets to 625ml bottles, and has positioned itself as both a hangover recovery solution and cocktail mixer. The company is now preparing for international expansion, particularly targeting the U.S. market, and is working on regulatory compliance with FDA requirements for packaging, ingredient disclosures, and health claims.

KRTL Holding Group (OTC:KRTL) has announced a strategic merger between its subsidiary KRTL Biotech and Industria Químico Farmacéutica Sigma Corp (SIGMA), a leading Bolivian pharmaceutical manufacturer. Under the agreement dated September 2, 2025, KRTL Biotech will acquire 99% of SIGMA's capital quotas in exchange for 490,000,000 common shares (49% ownership) of KRTL Biotech.

The transaction includes issuing one preferred share and a permanent board seat to SIGMA's CEO Patricia Wilstermann. This merger creates a fully integrated commercial channel strengthening both companies' presence in the U.S. and Latin America, enabling two-way pharmaceutical trade and manufacturing capabilities while maintaining SIGMA's local operational independence.

KRTL Holding Group Inc. (OTC: KRTL) has secured a significant court order from Utah's Third Judicial District Court to verify and remediate legacy shareholder records as part of its SEC Rule 15c2-11 compliance journey. The court-approved process includes sending certified notices to historical shareholders, implementing a 60-day documentation submission window, and potential share cancellation for non-responsive cases. This initiative aims to cleanse shareholder records of unverified entries, strengthen corporate governance, and facilitate Rule 144 resale eligibility. CEO Cesar Herrera emphasizes this as a crucial step toward restoring shareholder confidence and improving trading access.

KRTL Holding Group has announced the acquisition of Neurogen Brain Balancing, a California-based neurotechnology company specializing in brain balancing therapies and cognitive optimization systems. The acquisition involves KRTL obtaining 100% of Neurogen's equity through a stock-based structure with a profit-sharing agreement.

The deal positions Neurogen as a KRTL subsidiary, integrating advanced neurotechnology into KRTL's ecosystem. Neurogen's technology offers non-opioid, non-invasive treatment options for cognitive enhancement, stress reduction, and post-trauma recovery. The integration process includes brand alignment, financial system harmonization, and operational planning, supported by KRTL's Quality Management System and Enterprise Resource Planning infrastructure.

As part of the strategic integration, Neurogen will participate in real-world data research through connection with Centro de Investigaciones Químicas - CIQ S.R.L in Bolivia, contributing to global product validation efforts.

KRTL Holding Group (OTC: KRTL) has announced that its subsidiary KRTL Biotech Inc. has signed a Memorandum of Understanding (MOU) with Bolivia's Industria Químico Farmacéutica Sigma Corp for a strategic international merger. The agreement includes shared governance structure and consolidated financial oversight, with Sigma maintaining operational autonomy in Bolivia.

Key terms include Sigma receiving one Special 2021 Series A Preferred Share in KRTL Holding Group and board representation. Financial integration will be managed through SIGMARTL Corp, a U.S.-based entity. The merger aims to integrate Sigma's manufacturing operations and revenue streams into KRTL Biotech, facilitating U.S. market entry for Sigma's pharmaceutical products.

Sigma currently generates annual revenues exceeding $20 million, with facilities operating at 40% capacity. The merged entity projects potential revenue doubling within two years post-integration. The deal is expected to enhance operational efficiency and expand KRTL's presence in international pharmaceutical production.

KRTL Holding Group (OTC: KRTL) has announced a strategic expansion in Bolivia through a joint venture between its subsidiaries, KRTL Biotech and KRTL International, and Centro de Investigaciones Químicas (CIQ). Each subsidiary secured a 9.99% stake in 3451.5 acres of land in the Amazon region, totaling 689.9 acres.

The partnership aims to establish sustainable API extraction, research, and manufacturing facilities in Bolivia, with three key facilities planned in Quillacollo, Santa Cruz, and Cochabamba. CIQ, led by Dr. Bascope, specializes in extracting high-value botanical ingredients from Bolivia's diverse ecosystems.

Through this venture, KRTL Biotech will introduce CIQ's products, including cosmetics, raw materials, minerals, and APIs, to the U.S. market following FDA registration requirements. The collaboration also provides access to CIQ's exotic molecule library for potential pharmaceutical applications in pain management, anti-inflammatory treatments, and dermatology.

KRTL Holding Group has announced the successful FDA registration of Industria Químico Farmaceutica SIGMA CORP (SIGMA), a Bolivian pharmaceutical company, obtaining their Federal Establishment Identifier (FEI). This milestone enables access to the U.S. market and highlights the partnership between KRTL and SIGMA in advancing regulatory readiness.

The collaboration aims to leverage Bolivia's rich biodiversity and natural resources in the pharmaceutical sector. According to the U.S. Department of Commerce, Bolivia presents untapped potential in pharmaceutical manufacturing and export capabilities. The FDA registration demonstrates both companies' commitment to regulatory excellence and quality manufacturing, positioning Bolivian-manufactured pharmaceuticals for global market opportunities.

KRTL Biotech Inc., a wholly owned subsidiary of KRTL Holding Group Inc. (OTC: KRTL), has acquired a 55% majority stake in Skidmore Companies , now rebranded as Nutrivance Global. The acquisition leverages KRTL's Active Pharmaceutical Ingredients (APIs) portfolio with Nutrivance Global's established government and private distribution networks.

The deal includes a sophisticated data platform for real-world decision-making, enhancing distribution efficiency and partner insights. The partnership aims to expand distribution of KRTL's APIs, FDA-approved food and beverage products, and cosmetic lines internationally. A revenue-sharing structure has been implemented to ensure transparent management and accelerate market reach.

The collaboration combines Nutrivance Global's distribution expertise and regulatory compliance capabilities with KRTL's product portfolio, positioning both companies to address growing global demand for APIs and advanced solutions.